drugset / Trial / NCT00006124

Celecoxib in Treating Patients With Bladder Cancer

NCT00006124

Phase 2/3 Completed 152 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindPrevention

Summary

This randomized phase IIb/III trial is studying celecoxib to see how well it works in preventing disease recurrence in patients who have bladder cancer. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent the recurrence of bladder cancer

Timeline

Start
2000-06
Primary completion
2006-03
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified Oral